TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03709706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lete-cel
Description: lete-cel will be administered to eligible participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered to eligible participants.
Study: NCT04048850

Intervention type: DRUG
Intervention: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Description: Daily medication
Study: NCT02690064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute Antioxidant
Description: Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chronic Antioxidant
Description: Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Study: NCT04429542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCA101
Description: EGFR/TGFβ fusion monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCA101
Description: EGFR/TGFβ fusion monoclonal antibody
Study: NCT03709706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered to eligible participants.
Study: NCT05177978

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator (2 x chewable gummies/day, matched to shape and color without active ingredient)
Study: NCT02904330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K1-70 intramuscular or K1-70 intravenous
Description: Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
Study: NCT02312661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
Study: NCT04429542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD-1
Study: NCT01176006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduced-intensity hematopoietic stem cell
Description: stem cell transplant
Study: NCT02312661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
Study: NCT02268604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB 722 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02699645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
Description: 1 pill taken orally once daily for average of 72 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill taken orally once daily for average of 72 months
Study: NCT03624894

Intervention type: OTHER
Intervention: impression
Description: common polyvinylsiloxane oral impression
Study: NCT01448811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEP monitor
Description: In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI\>40, titrate up propofol dosage, AAI\<25, titrated down propofol dosage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ramsay Sedation Scale
Description: During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
Study: NCT01115634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibroblast
Description: 20 million cell in three injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fibroblast and gel
Description: 20 million cell in three injection plus filler
Study: NCT00954434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red wine
Description: intake of red wine on a daily basis
Study: NCT02589184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypergravity
Description: the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypergravity
Description: the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric load
Description: at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric load
Description: at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal gravity
Description: the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal gravity
Description: the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
Study: NCT01176006

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reduced-intensity hematopoietic stem cell
Description: stem cell transplant

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reduced-intensity hematopoietic stem cell
Description: stem cell transplant
Study: NCT00241813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM) Program
Description: Participants will take part in a mindfulness meditation (MM) program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM) Program
Description: Participants will take part in a mindfulness meditation (MM) program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control Program (CTL)
Description: Participants will take part in a health education control program (CTL)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifeskills Program (LP)
Description: Participants will take part in a lifeskills program (LP).
Study: NCT01176006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine(Fludara, Berlex Laboratories)
Description: 40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine(Fludara, Berlex Laboratories)
Description: 40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
Study: NCT00241813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifeskills Program (LP)
Description: Participants will take part in a lifeskills program (LP).
Study: NCT03111602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restrict polyphenol-rich foods
Description: dietary orientation to restrict polyphenol-rich foods
Study: NCT04216095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy (n=30)
Description: Right unilateral (RUL) ECT (n=15) or bitemporal (BT) ECT (n=15) using a Thymatron IV device (Somatics LLC, USA) twice weekly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Seizure Therapy (n=30)
Description: High-dose magnetic seizure therapy (HD-MST) over the vertex using Magstim Theta device (Magstim Company Limited, Whitfield, Wales, UK) at 100% maximal output of the device (constant), with pulse frequency 100Hz and train duration 10 seconds twice weekly.
Study: NCT02214524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair Hugger forced air warming system
Description: Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
Study: NCT04405947

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reverse Shoulder Arthroplasty
Description: implantation of a reversed shoulder prostheses through two different surgical approaches

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reverse Shoulder Arthroplasty
Description: implantation of a reversed shoulder prostheses through two different surgical approaches
Study: NCT02911753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Lemonade
Description: All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Tea
Description: All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored Water
Description: All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
Study: NCT01176006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide(CTX, Cytoxan)
Description: 14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation (TBI)
Description: 200 cGy on Day -1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (Busulfex)
Description: 3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor peripheral blood stem cell mobiliation and collection
Description: Donors undergo peripheral blood stem cell (PBSC) collection by apheresis will have their CD34 cells mobilized into the blood with filgrastim (Neupogen, Amgen)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Marrow Harvest Procedure
Description: Bone marrow from haploidentical related donors, and, in some cases, matched related donors will be harvested under routine conditions in the operating room. General or spinal anesthesia will be employed.
Study: NCT03671460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
Study: NCT03586180

Intervention type: BEHAVIORAL
Intervention: Medical Clowning for children
Description: Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.

Intervention type: BEHAVIORAL
Intervention: Medical Clowning for children
Description: Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
Study: NCT00573534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse
Description: Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
Study: NCT01572220

Intervention type: OTHER
Group type: OTHER
Intervention: UCA stress echocardiography or myocardial SPECT
Description: Comparative Effectiveness of cardiac stress imaging modalities

Intervention type: OTHER
Group type: OTHER
Intervention: UCA stress echocardiography or myocardial SPECT
Description: Comparative Effectiveness of cardiac stress imaging modalities
Study: NCT00816985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
Study: NCT01411904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagProbe (TM)
Description: CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
Study: NCT00095901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT03251300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daytime dosing of mirabegron
Description: All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nighttime dosing of mirabegron
Description: All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
Study: NCT03181581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: acoustic coupling fluid
Description: ultrasound images obtained with both ACF and Ringer's acetate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: acoustic coupling fluid
Description: ultrasound images obtained with both ACF and Ringer's acetate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's acetate
Description: ultrasound images obtained with Ringer's acetate only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's acetate
Description: ultrasound images obtained with Ringer's acetate only
Study: NCT02143414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy
Study: NCT03032315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)
Description: Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TWYNSTA(Telmisartan+Amlodipine besylate)
Description: TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
Study: NCT03092609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
Study: NCT02143414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo a blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo a blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study: NCT03092609

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
Study: NCT02143414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04214756

Intervention type: PROCEDURE
Intervention: Acute Pancreatitis
Description: All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
Study: NCT02143414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo a lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo a lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Sodium
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT04036188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone 0.1% daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone 0.1% daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 40,000 IU Vitamin D3 daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 40,000 IU Vitamin D3 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study: NCT03775265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo CT or MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo CT or MRI
Study: NCT00368355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: day-8 through day-5~3 g/m2 q 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: day-8 through day-5~3 g/m2 q 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: day-7 and day-6~45 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: day-7 and day-6~45 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~\>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~\>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: day-4 through day-1~175 cGy x 2 at 24 cGy/min

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: day-4 through day-1~175 cGy x 2 at 24 cGy/min

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem cells are infused on day 0
Study: NCT03775265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00368355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem cells are infused on day 0
Study: NCT05173402

Intervention type: DEVICE
Intervention: dentoalveolar compensation method
Description: orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw

Intervention type: DEVICE
Intervention: face mask
Description: orthopedic treatment was performed using a face mask.